Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations. [electronic resource]
Producer: 20070424Description: 805-11 p. digitalISSN:- 1699-048X
- ADP-ribosyl Cyclase 1 -- biosynthesis
- Adult
- Aged
- Aged, 80 and over
- Amino Acid Chloromethyl Ketones -- pharmacology
- Antineoplastic Agents -- administration & dosage
- Apoptosis -- drug effects
- Boronic Acids -- administration & dosage
- Bortezomib
- Caspase Inhibitors
- Caspases -- physiology
- Cysteine Proteinase Inhibitors -- pharmacology
- Dose-Response Relationship, Drug
- Drug Screening Assays, Antitumor
- Female
- Gene Rearrangement, B-Lymphocyte, Heavy Chain
- Genes, Immunoglobulin
- Humans
- I-kappa B Kinase -- antagonists & inhibitors
- I-kappa B Proteins -- metabolism
- Immunoglobulin Heavy Chains -- genetics
- Immunoglobulin Variable Region -- genetics
- Leukemia, Lymphocytic, Chronic, B-Cell -- genetics
- Male
- Middle Aged
- NF-kappa B -- antagonists & inhibitors
- Neoplasm Proteins -- antagonists & inhibitors
- Nitriles -- pharmacology
- Phosphorylation -- drug effects
- Protein Kinase Inhibitors -- administration & dosage
- Protein Processing, Post-Translational -- drug effects
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins c-bcl-6 -- genetics
- Pyrazines -- administration & dosage
- Sulfones -- pharmacology
- Tumor Cells, Cultured -- drug effects
- ZAP-70 Protein-Tyrosine Kinase -- biosynthesis
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.